NCL Technology Ventures

NCL Technology Ventures is a UK-based venture capital firm specializing in early-stage investments across the healthcare and life sciences sectors. Founded in 2010, the firm focuses on identifying and backing companies that are driving transformational change in healthcare, with a particular emphasis on innovation in areas such as therapeutics, medical technologies, and digital health. NCL's mission is to foster companies that are developing breakthrough solutions to address global health challenges, from preventive care to cutting-edge treatments​. The firm's investments typically range between €1.5M and €3M, with a strong focus on seed and Series A funding. NCL is deeply involved in the strategic development of its portfolio companies, providing both capital and operational expertise to help them navigate the complexities of the healthcare landscape. The firm's portfolio includes companies like TC BioPharm, which is pioneering allogeneic cell therapies, and Curesponse, a precision medicine startup. With offices in London and the US, NCL is well-positioned to support its portfolio globally, fostering partnerships and driving innovation in both European and American markets. Their team, led by experienced venture capitalists like Jerry Biggs and Jonathan Synett, brings decades of investment and entrepreneurial expertise to the table.